Japan’s Ministry of Health, Labor and Welfare approves Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech’s Darzalex (daratumumab), combined with Takeda’s Velcade (bortezomib), melphalan and prednisone, for newly diagnosed multiple myeloma (MM) patients who are ineligible for autologous stem cell transplant.
The first commercial sale will trigger a $7M milestone payment to licensor Genmab A/S (NASDAQ:GMAB).
Darzalex (combined with certain other drugs) was first approved there in September 2017 for relapsed/refractory MM.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.